

NCIC CLINICAL TRIALS GROUP

LUNG

DISEASE SITE COMMITTEE MEETING AGENDA

Delta Chelsea Hotel, Toronto, Ontario
Saturday, May 3, 2008 - 8:30 am – 4:15 pm (EST)
Room: Churchill A

Chair: Frances Shepherd

8:30 am	<u>WELCOME AND ANNOUNCEMENTS</u>	Dr. F. Shepherd
8:35 am	<u>SUB-COMMITTEE REPORTS</u>	
	Small Cell Radiation Mesothelioma and Thymoma Correlative Sciences	Dr. P. Ellis Dr. Y. Ung Dr. C. Lee Dr. M-S Tsao
9:15 am	<u>NON-SMALL CELL LUNG CANCER</u>	
	<u>Surgical Adjuvant and Neoadjuvant and Locally Advanced Trials</u>	
	BR.16 - Randomized placebo controlled trial of adjuvant selenium in completely resected stage I NSCLC (ECOG)	Dr. T. Waddell
	BR.19 - Randomized trial of adjuvant gefitinib versus placebo after complete resection of Stage IB, II IIIA NSCLC	Dr. G. Goss
	BRC.2 - ECOG 1505 Randomized trial of chemotherapy +/- bevacizumab in completely resected Stage IB-III A NSCLC	Dr. C. Butts
	BRC.2 - ECOG 1505 Randomized trial of chemotherapy +/- bevacizumab in completely resected Stage IB-III A NSCLC <i>Economic analysis</i>	Dr. N. Leigh
	BRC.5 - CALGB 140503 A Phase III randomized trial of lobectomy versus sub-lobar resection for small (<=2cm) peripheral NSCLC	Dr. J. Deslauriers
	BR.27 LUNG-ART Post-operative adjuvant radiation for completely resected N2 NSCLC	Dr. Yee Ung
10:30 am	Coffee Break (~ 15 min)	
11:15 am	<u>Advanced NSCLC</u>	
	BR.24 - Randomized trial of paclitaxel and carboplatin +/- AZD 2171 in advanced Non-SCLC	Dr. S. Laurie

BRC.4 -N0723 A Phase III biomarker validation study of second-line therapy in patients with advanced NSCLC randomized to pemetrexed versus erlotinib Dr. G. Liu

11:45 am **SMALL CELL LUNG CANCER**

BR.28 CONVERT – Once daily versus twice daily radiation for limited SCLC Dr. A. Bezjak

12:00 pm **Lunch (90 min.)**

1:30 pm **IND STUDIES**

IND.183 - Phase II trial of sunitinib in 2nd-line treatment of malignant mesothelioma Dr. S. Laurie

IND.190 – Phase I-II trial of etoposide/cisplatin + MK-0646 in extensive stage SCLC Dr. P. Ellis

Report from the IND Committee Dr. G. Goss

2:30 pm **RADIOTHERAPY STUDIES**

BR.25 - Hypofractionated radiotherapy for medically inoperable NSCLC Dr. P. Cheung

BRC.1 - PCI in Non-SCLC Dr. A. Sun

RTOG - PCI in SCLC Dr. A. Sun

3:00 pm **Coffee break (~ 15 min)**

3:15 pm **ECONOMIC AND DATA-BASE ANALYSES OF LUNG TRIALS**

Economic analyses active and planned Dr. N. Leigh
Database analyses Dr. F. Shepherd

3:45 pm **POTENTIAL NEW TRIALS UNDER CONSIDERATION**

Potential trials in previously treated NSCLC Dr. F. Shepherd
Etoposide/cisplatin/XRT +PI-3 Kinase inhibitor Dr. F. Shepherd
Phase I-II in limited SCLC

Nimotuzumab + XRT in medically inoperable peripheral NSCLC Dr. Y. Ung